Skip to main content
Premium Trial:

Request an Annual Quote

C2i Genomics, OncoDNA Enter Strategic Alliance for AI-Based Cancer Detection, Monitoring

NEW YORK – Cancer diagnostic company C2i Genomics said Monday that it has entered a strategic partnership with precision medicine company OncoDNA to pair C2i's artificial intelligence-based whole-genome sequencing and minimal residual disease cancer monitoring platform with OncoDNA's European network of cancer clinician-researchers.

The partnership, which expands C2i into Europe, will also support an interventional clinical trial led by Paris' Gustave Roussy Institute to test the clinical utility of escalating metastatic treatments in over 750 patients with high risk of cancer recurrence following standard of care. The study includes detection of circulating tumor DNA and seeks conclusive evidence of the benefits of C2i’s cancer detection technology across various solid cancers, including lung cancer, breast cancer, sarcoma, and gastrointestinal cancers. 

C2i and OncoDNA will provide cancer monitoring and analytic services for that trial.

C2i's partnership with OncoDNA follows other deals that have expanded C2i's market reach over the past year. These include alliances with NuProbe Global, Premier, and NovogeneAIT Genomics, taking the company into China, the US, and East Asia, respectively.

"C2i’s whole-genome technology provides ultra-high sensitivity with significantly reduced lab operation complexity, eliminating the need to develop a patient-specific assay, and allowing rapid and high-throughput solution for cancer patients across the EU," Jean-Pol Detiffe, founder of OncoDNA, said in a statement.